What is the story about?
Researchers announced on Thursday that an experimental drug for hepatitis B allows some patients to cease treatment without detectable signs of the virus,
indicating a potential "functional cure." The findings stem from two international studies involving patients who responded positively to the treatment. Approximately 20% of participants receiving the drug experienced significant reductions in viral levels, enabling their immune systems to manage the virus effectively. These results were presented at a scientific meeting in Barcelona, Spain, and published in the New England Journal of Medicine.
Overview of the Drug and Its Impact
The drug, known as bepirovirsen and developed by GSK and Ionis Pharmaceuticals, is currently undergoing fast-track review by the U.S. Food and Drug Administration, with a decision anticipated in October. It is also under consideration by regulatory bodies in Japan, China, and Europe.Chronic hepatitis B poses serious health risks, including liver cancer and liver failure, leading to approximately 1.1 million deaths globally each year. Current therapies often require lifelong adherence, which can be challenging for many patients.
Research Findings and Expert Opinions
Dr. Seng Gee Lim, a lead researcher from the National University Health System of Singapore, expressed optimism about the study's findings, stating, "We have not had a treatment which has come to this level of cure." Dr. Anna Lok, a hepatitis expert at the University of Michigan, called the results a significant advancement but urged for further investigation into the durability of the treatment's effects.Trial Details and Patient Responses
The trials involved 1,838 patients, with participants receiving either bepirovirsen or a placebo weekly for six months, alongside their standard antiviral medication. If the virus remained undetectable for six months after stopping the injections, they could also discontinue their regular treatment.Among the patients receiving bepirovirsen, 20% maintained undetectable virus levels for an additional six months post-treatment, achieving what researchers termed a "functional cure." Notably, this outcome was not observed in any patients who received the placebo.
Safety and Side Effects
GSK's vice president, Melanie Paff, explained that the drug operates by targeting the genetic components of the hepatitis B virus, inhibiting its replication and stimulating the immune response. Side effects reported included mild redness or pain at the injection site and temporary increases in liver enzyme levels.Research is ongoing to explore why certain patients respond more favorably to the treatment, particularly those with lower initial levels of the virus's surface protein.
